Investment
Orgenesis Secures up to USD 50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services
Orgenesis
PR-M11-22-05Nov 07, 2022
M&A
Catalent Acquires Orgenesis' Cell Therapy Unit
Catalent
PR-M01-20-NI-046Feb 03, 2020
Collaboration
Secant Group Announces Collaboration between Orgenesis and Atvio Biotech
Secant Group
PR-M08-18-NI-033Aug 09, 2018